A 38-year-old cisgender man with HIV recently completed the third dose in the hepatitis B vaccination series. An HBV surface antibody titer (anti-HBs) is checked 2 months after completion of the hepatitis B vaccine series, and it is less than 10 mIU/mL. He is taking antiretroviral therapy and laboratory studies conducted at the time he started the hepatitis B vaccine series showed a CD4 count of 298 cells/mm3 and an HIV RNA level below the limit of detection.
Which one of the following would be considered an acceptable option in this situation with nonresponse to the HBV vaccination?
Sign In or Register Progress Not Saved!
Since you are not signed in, your progress won't be saved.
Since you are not signed in, your progress won't be saved.
Question Last Updated
September 30th, 2023
September 30th, 2023
Steps to Acquire CE for this Question Bank Topic:
1
Answer
Answer all questions
2
Score 80%+
Answer correctly
3
Claim CE
Choose CNE or CME
4
Give Feedback
Complete survey
5